Therapeutic Potential of FXI Inhibitors: Hype or Hope?
- 29 July 2024
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 84 (9) , 1055-1070
Abstract
Significant advancements have shaped the landscape of anticoagulant therapy in the past two decades, including the introduction of direct oral anticoagulants (DOACs), characterized by favorable safety and efficacy profiles and reduced drug-to-drug or food interaction resulting in excellent patient compliance. However, residual concerns still exist with standard-of-care anticoagulant therapy, including the inability to use DOACs in several clinical settings and the need to further reduce the risk of bleeding. Recent improvements in the understanding of the mechanisms behind thrombus formation have led to the awareness that the intrinsic pathway of the coagulation cascade may play an important role in pathological thrombosis, but not in hemostasis. This has represented the rationale for targeting this pathway with factor XI (FXI) inhibitors, with the aim of uncoupling hemostasis and thrombosis. Clinical evidence from patients with FXI deficiency further supports this concept. A number of compounds with different mechanisms of action have been developed to target FXI (i.e., asundexian, abelacimab, Ionis-FXIRx, milvexian, osocimab, and Xisomab 3G). To date, the majority of available trials have not gone beyond completion of phase 2 and results are conflictive making it difficult to appraise the clinical benefit of these compounds in the different clinical settings where they have been tested (i.e., atrial fibrillation, acute ischemic stroke, acute myocardial infarction, end-stage renal disease, total knee arthroplasty). Moreover, the largest phase 3 randomized trial designed to test the efficacy of asundexian over apixaban in patients with atrial fibrillation, the OCEANIC-AF, has been prematurely stopped as a result of the inferior efficacy of asundexian. In this review we discuss the pharmacological properties and available evidence generated thus far for factor XI inhibitors, providing a perspective on the current state of these drugs.Keywords
This publication has 74 references indexed in Scilit:
- When Direct Oral Anticoagulants Should Not Be Standard TreatmentJACC, 2024
- Effects of Itraconazole and Diltiazem on the Pharmacokinetics and Pharmacodynamics of Milvexian, A Factor XIa InhibitorCardiology and Therapy, 2022
- Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXIRx in Patients With ESRDKidney International Reports, 2021
- Factor XI Inhibition to Uncouple Thrombosis From HemostasisJACC, 2021
- PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patientsCPT: Pharmacometrics & Systems Pharmacology, 2021
- Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee ArthroplastyJAMA, 2020
- Anticoagulation With an Inhibitor of Factors XIa and XIIa During Cardiopulmonary BypassJACC, 2019
- BAY 1213790, a fully human IgG1 antibody targeting coagulation factor XIa: First evaluation of safety, pharmacodynamics, and pharmacokineticsResearch and Practice in Thrombosis and Haemostasis, 2019
- Assessment of the Drug Interaction Potential of Unconjugated and GalNAc3-Conjugated 2′-MOE-ASOsMolecular Therapy Nucleic Acids, 2017
- Identification of an anticoagulant peptide that inhibits both fXIa and fVIIa/tissue factor from the blood-feeding nematode Ancylostoma caninumBiochemical and Biophysical Research Communications, 2010